Selenium and prostate cancer prevention: Insights from the Selenium and Vitamin E cancer prevention trial (SELECT)

Nutrients

Volumn 5, Issue 4, 2013, Pages 1122-1148

  Nicastro, Holly L ^a   Dunn, Barbara K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Prostate cancer; SELECT; Selenium

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; LYCOPENE; PLACEBO; SELENIUM; SELENOMETHIONINE; SELENOPROTEIN;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; FOLLOW UP; FOOD INTAKE; GENOTYPE; HUMAN; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PATIENT ATTITUDE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN INTAKE; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 84875964865     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5041122     Document Type: Review

References (84)

1. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations); Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., et al., Eds.; National Cancer Institute: Bethesda, MD, USA, 2012. Available online: http://seer.cancer.gov/csr/1975_2009_pops09/ (accessed on 13 December 2012).
2. American Cancer Society. Cancer Facts and Figures 2012; American Cancer Society: Atlanta, GA, USA, 2012.
3. Potosky, A.L.; Legler, J.; Albertsen, P.C.; Stanford, J.L.; Gilliland, F.D.; Hamilton, A.S.; Eley, J.W.; Stephenson, R.A.; Harlan, L.C. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst. 2000, 92, 1582-1592.
4. Stanford, J.L.; Feng, Z.; Hamilton, A.S.; Gilliland, F.D.; Stephenson, R.A.; Eley, J.W.; Albertsen, P.C.; Harlan, L.C.; Potosky, A.L. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate cancer outcomes study. JAMA 2000, 283, 354-360.
5. Wilson, K.M.; Giovannucci, E.L.; Mucci, L.A. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J. Androl. 2012, 14, 365-374.
6. Moyer, V.A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012, 157, 120-134.
7. Parnes, H.L. Prostate cancer prevention: Do the 5-ARIs make the grade? Am. J. Bioeth. 2011, 11, 30-31.
8. Thompson, I.M.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Miller, G.J.; Ford, L.G.; Lieber, M.M.; Cespedes, R.D.; Atkins, J.N.; Lippman, S.M.; et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349, 215-224.
9. Cohen, Y.C.; Liu, K.S.; Heyden, N.L.; Carides, A.D.; Anderson, K.M.; Daifotis, A.G.; Gann, P.H. Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 2007, 99, 1366-1374.
10. Andriole, G.L.; Bostwick, D.G.; Brawley, O.W.; Gomella, L.G.; Marberger, M.; Montorsi, F.; Pettaway, C.A.; Tammela, T.L.; Teloken, C.; Tindall, D.J.; et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010, 362, 1192-1202.
11. Theoret, M.R.; Ning, Y.-M.; Zhang, J.J.; Justice, R.; Keegan, P.; Pazdur, R. The risks and benefits of 5a-reductase inhibitors for prostate-cancer prevention. N. Engl. J. Med. 2011, 365, 97-99.
12. Heinonen, O.P.; Albanes, D.; Virtamo, J.; Taylor, P.R.; Huttunen, J.K.; Hartman, A.M.; Haapakoski, J.; Malila, N.; Rautalahti, M.; Ripatti, S.; et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 1998, 90, 440-446.
13. Clark, L.C.; Combs, G.F.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.; et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276, 1957-1963.
14. Terry, N.; Zayed, A.M.; De Souza, M.P.; Tarun, A.S. Selenium in Higher Plants. Annu. Rev. Plant. Physiol. Plant. Mol. Biol. 2000, 51, 401-432.
15. Li, H.F.; McGrath, S.P.; Zhao, F.J. Selenium uptake, translocation and speciation in wheat supplied with selenate or selenite. New Phytol. 2008, 178, 92-102.
16. Rayman, M.P. The importance of selenium to human health. Lancet 2000, 356, 233-241.
17. Beck, M.A.; Levander, O.A.; Handy, J. Selenium deficiency and viral infection. J. Nutr. 2003, 133, 1463S-1467S.
18. Dumont, E.; Vanhaecke, F.; Cornelis, R. Selenium speciation from food source to metabolites: A critical review. Anal. Bioanal. Chem. 2006, 385, 1304-1323.
19. Thomson, C.D.; Chisholm, A.; McLachlan, S.K.; Campbell, J.M. Brazil nuts: An effective way to improve selenium status. Am. J. Clin. Nutr. 2008, 87, 379-384.
20. Schrauzer, G.N. Nutritional selenium supplements: Product types, quality, and safety. J. Am. Coll. Nutr. 2001, 20, 1-4.
21. Medina, D.; Thompson, H.; Ganther, H.; Ip, C. Se-methylselenocysteine: A new compound for chemoprevention of breast cancer. Nutr. Cancer 2001, 40, 12-17.
22. Combs, G.F., Jr.; Gray, W.P. Chemopreventive agents: Selenium. Pharmacol. Ther. 1998, 79, 179-192.
23. Hatfield, D.L.; Gladyshev, V.N. The outcome of selenium and vitamin E cancer prevention trial (SELECT) reveals the need for better understanding of selenium biology. Mol. Interv. 2009, 9, 18-21.
24. Hatfield, D.L.; Gladyshev, V.N. How selenium has altered our understanding of the genetic code. Mol. Cell. Biol. 2002, 22, 3565-3576.
25. Davis, C.D.; Tsuji, P.A.; Milner, J.A. Selenoproteins and cancer prevention. Annu. Rev. Nutr. 2012, 32, 73-95.
26. Lee, K.H.; Jeong, D. Bimodal actions of selenium essential for antioxidant and toxic pro-oxidant activities: The selenium paradox (Review). Mol. Med. Rep. 2012, 5, 299-304.
27. Letavayova, L.; Vlckova, V.; Brozmanova, J. Selenium: From cancer prevention to DNA damage. Toxicology 2006, 227, 1-14.
28. Kobayashi, Y.; Ogra, Y.; Ishiwata, K.; Takayama, H.; Aimi, N.; Suzuki, K.T. Selenosugars are key and urinary metabolites for selenium excretion within the required to low-toxic range. Proc. Natl. Acad. Sci. USA 2002, 99, 15932-15936.
29. Kim, Y.S.; Milner, J. Molecular targets for selenium in cancer prevention. Nutr. Cancer 2001, 40, 50-54.
30. El-Bayoumy, K.; Sinha, R. Molecular chemoprevention by selenium: A genomic approach. Mutat. Res. 2005, 591, 224-236.
31. El-Bayoumy, K.; Sinha, R. Mechanisms of mammary cancer chemoprevention by organoselenium compounds. Mutat. Res. 2004, 551, 181-197.
32. Panel on Dietary Antioxidants and Related Compounds; Subcommittee on Upper Reference Levels of Nutrients; Subcommittee on Interpretation and Use of Dietary Reference Intakes; Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board; Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; National Academy Press: Washington, DC, USA, 2000; p. 506.
33. Levander, O.A.; Morris, V.C. Dietary selenium levels needed to maintain balance in North American adults consuming self-selected diets. Am. J. Clin. Nutr. 1984, 39, 809-815.
34. Whanger, P.D. Selenium and its relationship to cancer: An update. Br. J. Nutr. 2004, 91, 11-28.
35. Yang, G.; Zhou, R.; Yin, S.; Gu, L.; Yan, B.; Liu, Y.; Li, X. Studies of safe maximal daily dietary selenium intake in a seleniferous area in China. I. Selenium intake and tissue selenium levels of the inhabitants. J. Trace Elem. Electrolytes Health Dis. 1989, 3, 77-87.
36. Fulgoni, V.L., III; Keast, D.R.; Bailey, R.L.; Dwyer, J. Foods, fortificants, and supplements: Where do Americans get their nutrients? J. Nutr. 2011, 141, 1847-1854.
37. Bailey, R.L.; Gahche, J.J.; Lentino, C.V.; Dwyer, J.T.; Engel, J.S.; Thomas, P.R.; Betz, J.M.; Sempos, C.T.; Picciano, M.F. Dietary supplement use in the United States, 2003-2006. J. Nutr. 2011, 141, 261-266.
38. Bailey, R.L.; Fulgoni, V.L., III; Keast, D.R.; Dwyer, J.T. Dietary supplement use is associated with higher intakes of minerals from food sources. Am. J. Clin. Nutr. 2011, 94, 1376-1381.
39. Webber, M.M.; Perez-Ripoll, E.A.; James, G.T. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem. Biophys. Res. Commun. 1985, 130, 603-609.
40. Etminan, M.; FitzGerald, J.M.; Gleave, M.; Chambers, K. Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes Control. 2005, 16, 1125-1131.
41. Nelson, M.A.; Reid, M.; Duffield-Lillico, A.J.; Marshall, J.R. Prostate cancer and selenium. Urol. Clin. North. Am. 2002, 29, 67-70.
42. McCormick, D.L.; Rao, K.V.; Johnson, W.D.; Bosland, M.C.; Lubet, R.A.; Steele, V.E. Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prev. Res. (Phila.) 2010, 3, 381-392.
43. Ozten, N.; Horton, L.; Lasano, S.; Bosland, M.C. Selenomethionine and a-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev. Res. (Phila.) 2010, 3, 371-380.
44. Venkateswaran, V.; Klotz, L.H.; Ramani, M.; Sugar, L.M.; Jacob, L.E.; Nam, R.K.; Fleshner, N.E. A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev. Res. (Phila.) 2009, 2, 473-483.
45. Venkateswaran, V.; Fleshner, N.E.; Sugar, L.M.; Klotz, L.H. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res. 2004, 64, 5891-5896.
46. Wang, L.; Bonorden, M.J.; Li, G.X.; Lee, H.J.; Hu, H.; Zhang, Y.; Liao, J.D.; Cleary, M.P.; Lu, J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev. Res. (Phila) 2009, 2, 484-495.
47. Bespalov, V.G.; Panchenko, A.V.; Murazov Ia, G.; Chepik, O.F. Influence of sodium selenite on carcinogenesis of the prostate and other organs induced by methylnitrosourea and testosterone in rats. Vopr. Onkol. 2011, 57, 486-492.
48. Shamberger, R.J.; Frost, D.V. Possible protective effect of selenium against human cancer. Can. Med. Assoc. J. 1969, 100, 682-682.
49. Shamberger, R.J.; Willis, C.E. Selenium distribution and human cancer mortality. CRC Crit. Rev. Clin. Lab. Sci. 1971, 2, 211-221.
50. Schrauzer, G.N. Anticarcinogenic effects of selenium. Cell. Mol. Life Sci. 2000, 57, 1864-1873.
51. Brooks, J.D.; Metter, E.J.; Chan, D.W.; Sokoll, L.J.; Landis, P.; Nelson, W.G.; Muller, D.; Andres, R.; Carter, H.B. Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol. 2001, 166, 2034-2038.
52. Yoshizawa, K.; Willett, W.C.; Morris, S.J.; Stampfer, M.J.; Spiegelman, D.; Rimm, E.B.; Giovannucci, E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl. Cancer Inst. 1998, 90, 1219-1224.
53. World Cancer Research Fund; American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective; AICR: Washington DC, USA, 2007. Available online: http://www.dietandcancerreport.org/expert_report/index.php (accessed on 26 November 2012).
54. Yu, S.Y.; Zhu, Y.J.; Li, W.G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res. 1997, 56, 117-124.
55. Blot, W.J.; Li, J.Y.; Taylor, P.R.; Guo, W.; Dawsey, S.; Wang, G.Q.; Yang, C.S.; Zheng, S.F.; Gail, M.; Li, G.Y. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 1993, 85, 1483-1492.
56. Li, J.Y.; Taylor, P.R.; Li, B.; Dawsey, S.; Wang, G.Q.; Ershow, A.G.; Guo, W.; Liu, S.F.; Yang, C.S.; Shen, Q. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J. Natl. Cancer Inst. 1993, 85, 1492-1498.
57. Duffield-Lillico, A.J.; Dalkin, B.L.; Reid, M.E.; Turnbull, B.W.; Slate, E.H.; Jacobs, E.T.; Marshall, J.R.; Clark, L.C.; Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003, 91, 608-612.
58. Sabichi, A.L.; Lee, J.J.; Taylor, R.J.; Thompson, I.M.; Miles, B.J.; Tangen, C.M.; Minasian, L.M.; Pisters, L.L.; Caton, J.R.; Basler, J.W.; et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of L-selenomethionine: A Southwest Oncology Group Study. Clin. Cancer Res. 2006, 12, 2178-2184.
59. The ATBC Cancer Prevention Study Group. The a-tocopherol, beta-carotene lung cancer prevention study: Design, methods, participant characteristics, and compliance. Ann. Epidemiol. 1994, 4, 1-10.
60. Lippman, S.M.; Goodman, P.J.; Klein, E.A.; Parnes, H.L.; Thompson, I.M.; Kristal, A.R.; Santella, R.M.; Probstfield, J.L.; Moinpour, C.M.; Albanes, D.; et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J. Natl. Cancer Inst. 2005, 97, 94-102.
61. Klein, E.A.; Thompson, I.M.; Lippman, S.M.; Goodman, P.J.; Albanes, D.; Taylor, P.R.; Coltman, C. SELECT: The selenium and vitamin E cancer prevention trial: Rationale and design. Prostate Cancer Prostatic Dis. 2000, 3, 145-151.
62. Lippman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009, 301, 39-51.
63. Klein, E.A.; Thompson, I.M., Jr.; Tangen, C.M.; Crowley, J.J.; Lucia, M.S.; Goodman, P.J.; Minasian, L.M.; Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011, 306, 1549-1556.
64. Stranges, S.; Marshall, J.R.; Natarajan, R.; Donahue, R.P.; Trevisan, M.; Combs, G.F.; Cappuccio, F.P.; Ceriello, A.; Reid, M.E. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann. Intern. Med. 2007, 147, 217-223.
65. Bleys, J.; Navas-Acien, A.; Guallar, E. Selenium and diabetes: More bad news for supplements. Ann. Intern. Med. 2007, 147, 271-272.
66. Bleys, J.; Navas-Acien, A.; Guallar, E. Serum selenium and diabetes in U.S. adults. Diabetes Care 2007, 30, 829-834.
67. Goodman, P.J.; Hartline, J.A.; Tangen, C.M.; Crowley, J.J.; Minasian, L.M.; Klein, E.A.; Cook, E.D.; Darke, A.K.; Arnold, K.B.; Anderson, K.; et al. Moving a randomized clinical trial into an observational cohort. Clin. Trials 2012, 10, 131-142.
68. Lu, J.; Jiang, C.; Kaeck, M.; Ganther, H.; Vadhanavikit, S.; Ip, C.; Thompson, H. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem. Pharmacol. 1995, 50, 213-219.
69. Ip, C.; Birringer, M.; Block, E.; Kotrebai, M.; Tyson, J.F.; Uden, P.C.; Lisk, D.J. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J. Agric. Food Chem. 2000, 48, 2062-2070.
70. Ip, C.; Thompson, H.J.; Zhu, Z.; Ganther, H.E. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000, 60, 2882-2886.
71. Waters, D.J.; Shen, S.; Kengeri, S.S.; Chiang, E.C.; Morris, J.S.; Bostwick, D.G. Prostatic response to supranutritional selenium supplementation: Comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasis. Nutrients 2012, 4, 1650-1663.
72. Influence of Selenium on Biomarkers of Prostate Cancer Risk. Verified July 2011 by Penn State University, ClinicalTrials. gov Identifier: NCT01112449. Available online: http://clinicaltrials.gov/ ct2/show/NCT01112449 (accessed on 13 December 2012).
73. Dunn, B.K.; Richmond, E.S.; Minasian, L.M.; Ryan, A.M.; Ford, L.G. A nutrient approach to prostate cancer prevention: The selenium and vitamin E cancer prevention trial (SELECT). Nutr. Cancer 2010, 62, 896-918.
74. Waters, D.J.; Shen, S.; Glickman, L.T.; Cooley, D.M.; Bostwick, D.G.; Qian, J.; Combs, G.F.; Morris, J.S. Prostate cancer risk and DNA damage: Translational significance of selenium supplementation in a canine model. Carcinogenesis 2005, 26, 1256-1262.
75. Chiang, E.C.; Shen, S.; Kengeri, S.S.; Xu, H.; Combs, G.F.; Morris, J.S.; Bostwick, D.G.; Waters, D.J. Defining the optimal selenium dose for prostate cancer risk reduction: insights from the u-shaped relationship between selenium status, DNA damage, and apoptosis. Dose Response 2009, 8, 285-300.
76. Li, H.; Kantoff, P.W.; Giovannucci, E.; Leitzmann, M.F.; Gaziano, J.M.; Stampfer, M.J.; Ma, J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005, 65, 2498-2504.
77. Penney, K.L.; Schumacher, F.R.; Li, H.; Kraft, P.; Morris, J.S.; Kurth, T.; Mucci, L.A.; Hunter, D.J.; Kantoff, P.W.; Stampfer, M.J.; et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev. Res. (Phila.) 2010, 3, 604-610.
78. Combs, G.F., Jr.; Jackson, M.I.; Watts, J.C.; Johnson, L.K.; Zeng, H.; Idso, J.; Schomburg, L.; Hoeg, A.; Hoefig, C.S.; Chiang, E.C.; et al. Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br. J. Nutr. 2012, 107, 1514-1525.
79. Boyapati, S.M.; Shu, X.O.; Ruan, Z.X.; Dai, Q.; Cai, Q.; Gao, Y.T.; Zheng, W. Soyfood intake and breast cancer survival: A followup of the Shanghai Breast Cancer Study. Breast Cancer Res. Treat. 2005, 92, 11-17.
80. Freemantle, N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: Should we lock the crazy aunt in the attic? BMJ 2001, 322, 989-991.
81. Powles, T.J.; Ashley, S.; Tidy, A.; Smith, I.E.; Dowsett, M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl. Cancer Inst. 2007, 99, 283-290.
82. Bera, S.; Rosa, V.D.; Rachidi, W.; Diamond, A.M. Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? Mutagenesis 2013, 28, 127-134.
83. Ledesma, M.C.; Jung-Hynes, B.; Schmit, T.L.; Kumar, R.; Mukhtar, H.; Ahmad, N. Selenium and vitamin E for prostate cancer: Post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol. Med. 2011, 17, 134-143.
84. Nicastro, H.L.; Trujillo, E.B.; Milner, J.A. Nutrigenomics and cancer prevention. Curr. Nutr. Rep. 2012, 1, 37-43.